title: Significant link between sCD30 changes and HIV viremia in patients treated with HAART.
abstract: Elevated sCD30 levels were generally associated with poor prognosis in chronic HIV infection prior to the era of highly active antiretroviral therapy (HAART). Little information is available on sCD30 and HIV-1 viremia. In this study, the association between sCD30 and HIV-1 viremia was investigated in HIV-infected patients who underwent HAART. sCD30 was measured in 276 patients prior (T0) and 6 months after HAART (T6). Standard survival analyses were used to evaluate the prognostic value of sCD30 and sCD30 change from baseline to predict the virological response to HAART. Higher levels (>30 U/ml) of sCD30 prior to HAART were associated with relatively higher viremia (P = 0.0001) and tended to be associated with a lower chance of achieving virological success (P = 0.13). The median T6 sCD30 level in patients who concomitantly had viremia >500 copies/ml was higher than the median sCD30 level of those with viremia </=500 copies/ml (P = 0.002). Conversely, within the patients who achieved viral suppression on HAART, those who had concomitantly a larger reduction in sCD30 subsequently experienced a higher rate of virological failure (P = 0.04). A strong, but complex, link exists between sCD30 levels and HIV viremia in the era of HAART. The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success.
authors.affiliation: Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy. pricilla.biswas@hsr.it
authors.forename: Priscilla
authors.initials: P
authors.lastname: Biswas
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cozzi-Lepri
authors.forename: Fanny
authors.initials: F
authors.lastname: Delfanti
authors.forename: Andrea
authors.initials: A
authors.lastname: Galli
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Colangeli
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Moioli
authors.forename: Antonella
authors.initials: A
authors.lastname: Scarchilli
authors.forename: Nicola
authors.initials: N
authors.lastname: Abrescia
authors.forename: Gianmarco
authors.initials: G
authors.lastname: Vigevani
authors.forename: Antonella
authors.initials: A
authors.lastname: D'Arminio-Monforte
authors.forename: Roberto
authors.initials: R
authors.lastname: Novati
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy* / Q000821:virology
chemical_list: D017730:Ki-1 Antigen; D012367:RNA, Viral